Literature DB >> 31106729

Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat.

Oskar Jefsen1, Kristoffer Højgaard1, Sofie Laage Christiansen1, Betina Elfving1, David John Nutt2, Gregers Wegener1, Heidi Kaastrup Müller1.   

Abstract

OBJECTIVE: Psilocybin is a serotonin receptor agonist with a therapeutic potential for treatment-resistant depression and other psychiatric illnesses. We investigated whether the administration of psilocybin had an antidepressant-like effect in a rat model of depression.
METHODS: Using the Flinders Sensitive Line (FSL) rat model of depression, we assessed the antidepressant-like effect of psilocin and psilocybin, measured as a reduction in immobility time in the forced swim test (FST). We measured locomotor activity in an open field test (OFT) to control for stimulant properties of the drugs. We performed a set of experiments to test different doses, treatment paradigms, and timing of the tests in relation to the drug administration.
RESULTS: Psilocin and psilocybin showed no effect on immobility, struggling, or swimming behaviour in the FST and no effect on locomotor activity in the OFT. FSL rats did show significantly more immobility than their control strain, the Flinders Resistant Line, as expected.
CONCLUSION: Psilocin and psilocybin showed no antidepressant-like effect in the FSL rats, despite a positive effect in humans. This suggests that other animal models of depression and other behavioural tests may be more appropriate for translational studies in the effects of psilocybin.

Entities:  

Keywords:  antidepressive agents; hallucinogens; preclinical drug evaluation; psilocybin

Mesh:

Substances:

Year:  2019        PMID: 31106729     DOI: 10.1017/neu.2019.15

Source DB:  PubMed          Journal:  Acta Neuropsychiatr        ISSN: 0924-2708            Impact factor:   3.403


  9 in total

1.  Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior.

Authors:  Adam Wojtas; Agnieszka Bysiek; Agnieszka Wawrzczak-Bargiela; Zuzanna Szych; Iwona Majcher-Maślanka; Monika Herian; Marzena Maćkowiak; Krystyna Gołembiowska
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

2.  Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.

Authors:  Antonio Inserra; Justine P Enns; Danilo De Gregorio; Athanasios Markopoulos; Michael Pileggi; Youssef El Rahimy; Martha Lopez-Canul; Stefano Comai; Gabriella Gobbi
Journal:  Neuropsychopharmacology       Date:  2022-03-17       Impact factor: 8.294

3.  Chronic Treatment With Psilocybin Decreases Changes in Body Weight in a Rodent Model of Obesity.

Authors:  Joyce Huang; Michelle Pham; William J Panenka; William G Honer; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2022-05-18       Impact factor: 5.435

Review 4.  Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.

Authors:  John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane
Journal:  Front Psychiatry       Date:  2021-12-17       Impact factor: 4.157

5.  Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism.

Authors:  Marcus W Meinhardt; Simone Pfarr; Grégory Fouquet; Cathrin Rohleder; Manuela L Meinhardt; Janet Barroso-Flores; Rebecca Hoffmann; Jérôme Jeanblanc; Elisabeth Paul; Konstantin Wagner; Anita C Hansson; Georg Köhr; Nils Meier; Oliver von Bohlen Und Halbach; Richard L Bell; Heike Endepols; Bernd Neumaier; Kai Schönig; Dusan Bartsch; Mickaël Naassila; Rainer Spanagel; Wolfgang H Sommer
Journal:  Sci Adv       Date:  2021-11-17       Impact factor: 14.136

Review 6.  A systematic review of studies investigating the acute effects of N-methyl-D-aspartate receptor antagonists on behavioural despair in normal animals suggests poor predictive validity.

Authors:  Martin Viktorov; Matthew P Wilkinson; Victoria C E Elston; Medi Stone; Emma S J Robinson
Journal:  Brain Neurosci Adv       Date:  2022-03-12

7.  Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats.

Authors:  Piotr Popik; Adam Hogendorf; Ryszard Bugno; Shaun Yon-Seng Khoo; Pawel Zajdel; Natalia Malikowska-Racia; Agnieszka Nikiforuk; Joanna Golebiowska
Journal:  Psychopharmacology (Berl)       Date:  2022-03-02       Impact factor: 4.415

8.  A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.

Authors:  Niloufar Pouyan; Zahra Halvaei Khankahdani; Farnaz Younesi Sisi; Yena Lee; Joshua D Rosenblat; Kayla M Teopiz; Leanna M W Lui; Mehala Subramaniapillai; Kangguang Lin; Flora Nasri; Nelson Rodrigues; Hartej Gill; Orly Lipsitz; Bing Cao; Roger Ho; David Castle; Roger S McIntyre
Journal:  CNS Drugs       Date:  2022-09-12       Impact factor: 6.497

Review 9.  Natural Psychoplastogens As Antidepressant Agents.

Authors:  Jakub Benko; Stanislava Vranková
Journal:  Molecules       Date:  2020-03-05       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.